Systasy’s technology enables insights across the drug discovery pipeline, from the identification of novel targets and combinatorial drug screening to patient stratification. For this, Systasy leverages highly multiplexed pathway activity screens and patient-derived human disease models to understand complex disease.

Further, Systasy’s platform derives AI-driven unique insights from human biology to generate ultra-large, high-quality data like AI-powered stratification of patient groups and AI-powered prediction, identification, and validation of biomarkers. In addition, the Company offers viral tropism profiling for gene therapy development.

Systasy’s vision is to discover breakthrough therapies that transform the lives of patients who are affected by disorders of the brain, for which few effective treatments exist. We want to help conquer even the most challenging diseases and make a meaningful impact on global health. By integrating patient derived cellular disease models, pathway monitoring, and treatment testing, Systasy aims to increase the success rate in drug discovery significantly and revolutionize the way brain disorders can be treated.

Systasy was founded in 2012 by Dr Wichert, Dr Wehr and Professor Dr Rossner, as a spin-off from the Max Planck Institute for Experimental Medicine, Göttingen, Germany. Currently, the main headquarters are located in Munich, Germany.